Current ReadingsCurrent Readings: Percutaneous Ablation for Pulmonary Metastatic Disease
Section snippets
Introduction and General Principles
The traditional treatment for metastatic cancer has been systemic medical therapy. However, for certain patients with metastases confined to one or few sites, termed oligometastatic disease, local means of controlling these sites of disease may prolong survival and palliate symptoms, and in some cases may result in long-term disease-free survival.1 The treatment of oligometastatic disease to the lung demands a case-by-case, multidisciplinary approach. In properly selected patients without
Complications After 1000 Lung Radiofrequency Ablation Sessions in 420 Patients: A Single Center’s Experiences
Kashima M, Yamakado K, Takaki H, et al. Am J Roentgenol 197:W576, 2011
Percutaneous ablation is minimally invasive and is generally safe and well tolerated, with low rates of morbidity and very low procedure-related mortality. By far the most frequent complication is pneumothorax, occurring in approximately 30%-50% of patients. Most postablation pneumothoraces are asymptomatic or mildly symptomatic and can be managed with observation. However, chest tube placement may be required in
Treatment of Pulmonary Colorectal Metastases by Radiofrequency Ablation
Petre EN, Jia X, Thornton RH, et al. Clin Colorectal Cancer 12:37-44, 2013
Metastatic colorectal cancer is among the most frequent and best studied indications for percutaneous ablation.18, 19 Of the approximately 20% of colorectal cancer patients who have metastatic disease at presentation, as many as 17% have lung metastases.20 Recurrent disease after primary resection occurs in the lung approximately 5% of the time, second only to the liver as the most common site.20, 21 Expected survival in
Outcome After Radiofrequency Ablation of Sarcoma Lung Metastases
Koelblinger C, Strauss S, Gillams A. Cardiovasc Intervent Radiol 37(1):147-153, 2014
Metastatic sarcoma carries a poor prognosis. The expected survival with best systemic medical therapy is only 8-12 months.31 The lung is the most common organ involved by metastatic sarcoma, and survival can be improved with surgical resection. However, not all patients are suitable surgical candidates, and there is a limit to how much lung tissue can be resected because of a decrease in pulmonary reserve
Local Progression After Radiofrequency Ablation for Pulmonary Metastases
Von Meyenfeldt EM, Prevoo W, Peyrot D, et al. Cancer 117:3781-3787, 2011
Fewer data exist specific to other primary tumor types, but outcomes have been described in smaller series of patients with metastatic renal cell carcinoma,35, 36 hepatocellular carcinoma,37 melanoma,38, 39, 40 and esophageal squamous cell carcinoma.41 Von Meyenfeldt et al10 analyzed data from 90 consecutive RFAs performed in 46 patients. In total, 14 patients had metastatic colorectal cancer, 12 had metastatic sarcoma, 4
Factors Affecting Local Progression After Percutaneous Cryoablation of Lung Tumors
Yashiro H, Nakatsuka S, Inoue M, et al. J Vasc Interv Radiol 24:813, 2013
There has recently been interest in the identification of risk factors for local recurrence following percutaneous ablation. The size of the target lesion has been well described as such a risk factor, with lesions larger than 3 cm demonstrating poorer outcomes.42 However, if additional robust risk factors can be established, it may allow better selection of ideal lesions for treatment with ablation, and inform
Factors Influencing Local Tumor Control in Patients With Neoplastic Pulmonary Nodules Treated With Microwave Ablation: A Risk Factor Analysis
Vogl TJ, Worst TS, Naguib NN, et al. Am J Roentgenol 200:665, 2013
Vogl et al12 recently reported results of 91 tumor microwave ablations in 57 patients. Of the 91 ablated lesions, 76 were metastases from extrathoracic primary tumors, all of them smaller than 3 cm. Local progression occurred in 30 tumors (33%) after a mean time of 8.3 months. Candidate risk factors included in their analysis were shape of the index tumor (round or oval vs irregular), margin (clear vs ill-defined), pleural
Commentary
Percutaneous ablation of thoracic malignancies is a relatively recently developed procedure, with the first human cases reported in 2000,43 and data concerning its safety and efficacy in treating pulmonary metastatic disease are still forthcoming. In multiple studies, including the large series by Kashima et al7 reviewed earlier, the safety profile of percutaneous ablation has been well characterized. It is a safe procedure overall, with very low expected mortality. Pneumothorax is a relatively
Conclusion
Percutaneous image-guided ablation is a technique for maintaining local control of metastatic lung lesions that may, in selected patients, confer a survival benefit over no treatment or systemic therapy alone. Although the currently accepted treatment for oligometastatic pulmonary disease is surgical resection, the existing body of literature, including the recent investigations reviewed earlier, supports a role for percutaneous ablation as an important therapeutic option for nonsurgical and
References (46)
- et al.
Surgical resection of pulmonary metastases from colorectal cancer: A systematic review of published series
Ann Thorac Surg
(2007) - et al.
Mechanisms of tissue injury in cryosurgery
Cryobiology
(1998) - et al.
Treatment of pulmonary colorectal metastases by radiofrequency ablation
Clin Colorectal Cancer
(2013) - et al.
Factors affecting local progression after percutaneous cryoablation of lung tumors
J Vasc Interv Radiol
(2013) - et al.
CT-guided thin needles percutaneous cryoablation (PCA) in patients with primary and secondary lung tumors: A preliminary experience
Eur J Radiol
(2013) - et al.
Percutaneous cryoablation of lung tumors: Feasibility and safety
J Vasc Interv Radiol
(2012) - et al.
Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: A multicenter study
Surgery
(2007) - et al.
Response to radiofrequency ablation of pulmonary tumours: A prospective, intention-to-treat, multicenter clinical trial (the RAPTURE study)
Lancet Oncol
(2008) - et al.
Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: A multicenter study in Japan
J Vasc Interv Radiol
(2007) - et al.
Percutaneous radiofrequency ablation for pulmonary metastases from colorectal cancer: Midterm results in 27 patients
J Vasc Interv Radiol
(2007)
Long-term survival after radiofrequency ablation for pulmonary metastasis from hepatocellular carcinoma: Report of two cases
J Vasc Interv Radiol
Two cases of pulmonary melanoma metastasis treated with radiofrequency: An alternative to surgical excision
Ann Dermatol Venereol
The role of local therapy in the management of lung and liver oligometastases
Nat Rev Clin Oncol
Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases
J Thorac Cardiovasc Surg
Optimizing the protocol for pulmonary cryoablation: A comparison of a dual- and triple-freeze protocol
Cardiovasc Intervent Radiol
Laser ablation of metastatic lesions of the lung: Long-term outcome
Am J Roentgenol
Complications after 1000 lung radiofrequency ablation sessions in 420 patients: A single center’s experiences
Am J Roentgenol
Outcome after radiofrequency ablation of sarcoma lung metastases
Cardiovasc Intervent Radiol
Local progression after radiofrequency ablation for pulmonary metastases
Cancer
Factors influencing local tumor control in patients with neoplastic pulmonary nodules treated with microwave ablation: A risk-factor analysis
Am J Roentgenol
Pulmonary radiofrequency ablation: Long-term safety and efficacy in 153 patients
Radiology
Complications of microwave and radiofrequency lung ablation: Personal experience and review of the literature
Radiol Med
CT-guided percutaneous cryoablation of central lung tumors
Diagn Interv Radiol
Cited by (10)
Pulmonary metastasectomy for suspected pancreaticobiliary cancer
2016, Journal of Thoracic and Cardiovascular SurgerySpecialty Imaging: Thoracic Neoplasms
2016, Specialty Imaging: Thoracic NeoplasmsAblation of pulmonary neoplasms: review of literature and future perspectives
2023, Polish Journal of Radiology